Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy
- PMID: 36764322
- DOI: 10.1016/S1474-4422(22)00471-9
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy
Abstract
Multiple sclerosis is a chronic inflammatory disease of the CNS that results from the interplay between heritable and environmental factors. Mounting evidence from different fields of research supports the pivotal role of the Epstein-Barr virus (EBV) in the development of multiple sclerosis. However, translating this knowledge into clinically actionable information requires a better understanding of the mechanisms linking EBV to pathophysiology. Ongoing research is trying to clarify whether EBV causes neuroinflammation via autoimmunity or antiviral immunity, and if the interaction of EBV with genetic susceptibility to multiple sclerosis can explain why a ubiquitous virus promotes immune dysfunction in susceptible individuals. If EBV also has a role in driving disease activity, the characterisation of this role will help diagnosis, prognosis, and treatment in people with multiple sclerosis. Ongoing clinical trials targeting EBV and new anti-EBV vaccines provide hope for future treatments and preventive interventions.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests GG declares consulting or speaker fees from AbbVie, Aslan, Atara Bio, Biogen, Bristol Myers Squibb–Celgene, GlaxoSmithKline, GW Pharma, Janssen–Actelion, Japanese Tobacco, Jazz Pharmaceuticals, LifNano, Merck & Co, Merck KGaA–EMD Serono, Moderna, Novartis, Sanofi Genzyme, Roche-Genentech, and Teva Pharmaceuticals. MS declares speaking honoraria, research support from, and participation on an advisory board for Biogen, Bristol Myers Squibb, Merck, Novartis, Sanofi, Hoffmann-La Roche, and Viatris, and a patent: Epstein-Barr virus genotypic variants and uses thereof as risk predictors, biomarkers and theraputic targets of multiple sclerosis. FA declares participation on an advisory board for Hoffmann-La Roche.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical